Vitiligo
Conditions
Interventions
Dose escalation group:It adopts a "3+3" dose escalation design. Subjects were sequentially assigned to one of three dose groups, with a concentration of 2×105/mL in the low-dose group, 2×106/mL in the
A seven-day safety assessment for all participants in the previous dose group was completed before the next dose group could be conducted. If the criteria for terminating the trial are met during the
Case expansion group (control group):Tacrolimus in combination with 308 phototherapy
Case Expansion Group (Experimental Group):Hair follicle organoid therapy
Sponsors
General Hospital of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age> 18 years old 2. Clinically diagnosed vitiligo and in the stable stage of disease: VIDA score is 0; Clinical features: vitiligo is porcelain-white with well-defined or pigmented margins; No homomorphic reaction (> = 1 year); Wood lamp: the lesion is white in color, the boundary is clear, and the area of the lesion under the Wood lamp <= visual area; 3. Vitiligo lesions with similar lesions in the same segment of the body; 4. Sign the informed consent form and be able to receive hair follicle organoid therapy and follow-up follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with special conditions such as tumors, acute infections, insufficiency of vital organs, and pregnancy; 2. Patients who are already receiving other clinical drug trials or other gene therapy or cell therapy; 3. Patients with severe scar constitution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in vitiligo area;VISA; | — |
Countries
China
Contacts
Public ContactWang Wenjuan
General Hospital of the Chinese People's Liberation Army
Outcome results
None listed